Intermittent preventive sulfadoxine-pyrimethamine treatment of primigravidae reduces levels of plasma immunoglobulin G, which protects against pregnancy-associated Plasmodium falciparum malaria

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Intermittent preventive sulfadoxine-pyrimethamine treatment of primigravidae reduces levels of plasma immunoglobulin G, which protects against pregnancy-associated Plasmodium falciparum malaria. / Staalsoe, Trine; Shulman, Caroline E; Dorman, Edgar K; Kawuondo, Ken; Marsh, Kevin; Hviid, Lars.

In: Infection and Immunity, Vol. 72, No. 9, 2004, p. 5027-30.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Staalsoe, T, Shulman, CE, Dorman, EK, Kawuondo, K, Marsh, K & Hviid, L 2004, 'Intermittent preventive sulfadoxine-pyrimethamine treatment of primigravidae reduces levels of plasma immunoglobulin G, which protects against pregnancy-associated Plasmodium falciparum malaria', Infection and Immunity, vol. 72, no. 9, pp. 5027-30. https://doi.org/10.1128/IAI.72.9.5027-5030.2004

APA

Staalsoe, T., Shulman, C. E., Dorman, E. K., Kawuondo, K., Marsh, K., & Hviid, L. (2004). Intermittent preventive sulfadoxine-pyrimethamine treatment of primigravidae reduces levels of plasma immunoglobulin G, which protects against pregnancy-associated Plasmodium falciparum malaria. Infection and Immunity, 72(9), 5027-30. https://doi.org/10.1128/IAI.72.9.5027-5030.2004

Vancouver

Staalsoe T, Shulman CE, Dorman EK, Kawuondo K, Marsh K, Hviid L. Intermittent preventive sulfadoxine-pyrimethamine treatment of primigravidae reduces levels of plasma immunoglobulin G, which protects against pregnancy-associated Plasmodium falciparum malaria. Infection and Immunity. 2004;72(9):5027-30. https://doi.org/10.1128/IAI.72.9.5027-5030.2004

Author

Staalsoe, Trine ; Shulman, Caroline E ; Dorman, Edgar K ; Kawuondo, Ken ; Marsh, Kevin ; Hviid, Lars. / Intermittent preventive sulfadoxine-pyrimethamine treatment of primigravidae reduces levels of plasma immunoglobulin G, which protects against pregnancy-associated Plasmodium falciparum malaria. In: Infection and Immunity. 2004 ; Vol. 72, No. 9. pp. 5027-30.

Bibtex

@article{91405980a03411dd86a6000ea68e967b,
title = "Intermittent preventive sulfadoxine-pyrimethamine treatment of primigravidae reduces levels of plasma immunoglobulin G, which protects against pregnancy-associated Plasmodium falciparum malaria",
abstract = "Pregnancy-associated malaria (PAM) is an important cause of maternal and neonatal suffering. It is caused by Plasmodium falciparum capable of inhabiting the placenta through expression of particular variant surface antigens (VSA) with affinity for proteoglycans such as chondroitin sulfate A. Protective immunity to PAM develops following exposure to parasites inhabiting the placenta, and primigravidae are therefore particularly susceptible to PAM. The adverse consequences of PAM in primigravidae are preventable by intermittent preventive treatment (IPTp), where women are given antimalarials at specified intervals during pregnancy, but this may interfere with acquisition of protective PAM immunity. We found that Kenyan primigravidae receiving sulfadoxine-pyrimethamine IPTp had significantly lower levels of immunoglobulin G (IgG) with specificity for the type of parasite-encoded VSA-called VSA(PAM)-that specifically mediate protection against PAM than did women receiving a placebo. VSA(PAM)-specific IgG levels depended on the number of IPTp doses received and were sufficiently low to be of clinical concern among multidose recipients. Our data suggest that IPTp should be extended to women of all parities, in line with current World Health Organization recommendations.",
author = "Trine Staalsoe and Shulman, {Caroline E} and Dorman, {Edgar K} and Ken Kawuondo and Kevin Marsh and Lars Hviid",
note = "Keywords: Animals; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Drug Administration Schedule; Drug Combinations; Female; Humans; Immunoglobulin G; Malaria, Falciparum; Pregnancy; Pregnancy Complications, Parasitic; Pregnancy Trimester, Third; Pyrimethamine; Sulfadoxine",
year = "2004",
doi = "10.1128/IAI.72.9.5027-5030.2004",
language = "English",
volume = "72",
pages = "5027--30",
journal = "Infection and Immunity",
issn = "0019-9567",
publisher = "American Society for Microbiology",
number = "9",

}

RIS

TY - JOUR

T1 - Intermittent preventive sulfadoxine-pyrimethamine treatment of primigravidae reduces levels of plasma immunoglobulin G, which protects against pregnancy-associated Plasmodium falciparum malaria

AU - Staalsoe, Trine

AU - Shulman, Caroline E

AU - Dorman, Edgar K

AU - Kawuondo, Ken

AU - Marsh, Kevin

AU - Hviid, Lars

N1 - Keywords: Animals; Antibodies, Protozoan; Antigens, Protozoan; Antimalarials; Drug Administration Schedule; Drug Combinations; Female; Humans; Immunoglobulin G; Malaria, Falciparum; Pregnancy; Pregnancy Complications, Parasitic; Pregnancy Trimester, Third; Pyrimethamine; Sulfadoxine

PY - 2004

Y1 - 2004

N2 - Pregnancy-associated malaria (PAM) is an important cause of maternal and neonatal suffering. It is caused by Plasmodium falciparum capable of inhabiting the placenta through expression of particular variant surface antigens (VSA) with affinity for proteoglycans such as chondroitin sulfate A. Protective immunity to PAM develops following exposure to parasites inhabiting the placenta, and primigravidae are therefore particularly susceptible to PAM. The adverse consequences of PAM in primigravidae are preventable by intermittent preventive treatment (IPTp), where women are given antimalarials at specified intervals during pregnancy, but this may interfere with acquisition of protective PAM immunity. We found that Kenyan primigravidae receiving sulfadoxine-pyrimethamine IPTp had significantly lower levels of immunoglobulin G (IgG) with specificity for the type of parasite-encoded VSA-called VSA(PAM)-that specifically mediate protection against PAM than did women receiving a placebo. VSA(PAM)-specific IgG levels depended on the number of IPTp doses received and were sufficiently low to be of clinical concern among multidose recipients. Our data suggest that IPTp should be extended to women of all parities, in line with current World Health Organization recommendations.

AB - Pregnancy-associated malaria (PAM) is an important cause of maternal and neonatal suffering. It is caused by Plasmodium falciparum capable of inhabiting the placenta through expression of particular variant surface antigens (VSA) with affinity for proteoglycans such as chondroitin sulfate A. Protective immunity to PAM develops following exposure to parasites inhabiting the placenta, and primigravidae are therefore particularly susceptible to PAM. The adverse consequences of PAM in primigravidae are preventable by intermittent preventive treatment (IPTp), where women are given antimalarials at specified intervals during pregnancy, but this may interfere with acquisition of protective PAM immunity. We found that Kenyan primigravidae receiving sulfadoxine-pyrimethamine IPTp had significantly lower levels of immunoglobulin G (IgG) with specificity for the type of parasite-encoded VSA-called VSA(PAM)-that specifically mediate protection against PAM than did women receiving a placebo. VSA(PAM)-specific IgG levels depended on the number of IPTp doses received and were sufficiently low to be of clinical concern among multidose recipients. Our data suggest that IPTp should be extended to women of all parities, in line with current World Health Organization recommendations.

U2 - 10.1128/IAI.72.9.5027-5030.2004

DO - 10.1128/IAI.72.9.5027-5030.2004

M3 - Journal article

C2 - 15321995

VL - 72

SP - 5027

EP - 5030

JO - Infection and Immunity

JF - Infection and Immunity

SN - 0019-9567

IS - 9

ER -

ID: 6746939